PATIENT IDENTIFICATION

Are your patients like Jamie-Lynn ready for something different?

Real patient taking KESIMPTA who was compensated for time. Individual results may vary.

For relapsing MS patients, disease activity can mean disability progression¹

More frequent relapses, MRI activity, and new or worsening symptoms are all signs of active relapsing MS.^1,2

*Results from the MS in America Study, an online survey conducted in 2013 and completed by 2562 adult MS patients who were US residents or citizens living abroad.^3
†Analysis of US Symphony Anonymous Patient Level Data from November 2019-October 2020 pertaining to patients with MS. High efficacy therapies include ocrelizumab, natalizumab, alemtuzumab, fingolimod, siponimod, cladribine, and ozanimod.^4
‡A retrospective analysis of outcomes in newly diagnosed adult patients (N=1661) with ≥1 DMT claims of interferon, glatiramer acetate, or dimethyl fumarate from January 2016-March 2018 who were identified using a large US administrative claims database.^5,6

Meet a few of the more than 30,000 patients prescribed KESIMPTA® (ofatumumab) as a first-line treatment, or after experience with other DMTs^7§

Kristin was ready for a different choice to manage her disease activity.

Despite being treated with a DMT, Kristin continued to be affected by relapsing MS.

Clinical factors:

• Experienced recent relapse despite being on an oral first-line treatment

• Evidence of lesion activity in recent MRI

Non-clinical factors:

• Continued relapses despite treatment

• Wants to find a treatment that works for her

• Wants to reduce relapses in her life

Rachel loves to travel. She doesn't love dealing with relapsing MS.

After trying 2 DMTs, Rachel was looking for more control over disease activity.

Clinical factors:

• Previously on Aubagio®

• 2 new lesions on recent MRI

• 2 separate neurologists recommended KESIMPTA

Non-clinical factors:

• Worried about potential side effects

• Wants less frequent dosing

Being diagnosed with relapsing MS was overwhelming.

Walt wanted a treatment that could help manage his relapsing MS activity.

Clinical factors:

• An MRI for severe headache led to recent relapsing MS diagnosis

• No previous DMT

Non-clinical factors:

• Dislikes needles, refused infusions

• Wants to treat at home

• Feels at ease with Sensoready^® Pen, despite initial concern about injections

Kristin, Rachel, and Walt are real patients taking KESIMPTA who were compensated for their time. Individual results may vary.

Effect of high efficacy therapy on RMS when started earlier^|| vs later in a retrospective, observational analysis^8,9 
 

Cumulative risk of confirmed disability progression, measured from disease onset⁸

Adapted from He A, et al. Lancet Neurol. 2020.

In a 2020 retrospective international observational study, high efficacy therapy commenced within 2 years of disease onset was associated with less disability after 6-10 years of treatment, than when commenced later in the disease course. The group that received early high efficacy therapy started with more active RMS (based on EDSS score [2.54 vs 1.83]).⁸

High efficacy therapies included in the analysis were rituximab, ocrelizumab, alemtuzumab, and natalizumab. Other treatments included interferon, glatiramer acetate, and orals (fingolimod, teriflunomide, dimethyl fumarate, cladribine).⁸

No conclusions of statistical or clinical significance can be drawn. Consider retrospective observational study limitations when interpreting data. Further studies are needed to confirm findings.

A DMT is labeled as higher efficacy when the data show a more favorable treatment impact on at least relapses and disability progression. Some experts also prefer to evaluate MRI scans in considering relative efficacy.¹⁰

B-cell depletion is a key target for reducing RMS activity^8-11

More and more physicians are choosing to start patients earlier with B-cell therapy, doubling prescription rates since 2016

Annual new prescription share of B-cell therapies^12-14¶

B-cell therapies account for 60% OF ALL NEW-TO-BRAND PRESCRIPTIONS from health care providers^14¶

Experience with KESIMPTA keeps growing

^§Based on Novartis contracted specialty pharmacy and copay claims from launch through September 30, 2023.^{7       
||}Within 2 years of disease onset.      
^¶Based on annual new prescriptions share data from 2018 through August 2023. B-cell therapies include KESIMPTA® (ofatumumab), Ocrevus® (ocrelizumab), and Briumvi® (ublituximab-xiiy). KESIMPTA was approved in August 2020.^{12-14       
#}Based on patient Start Forms completed through September 15, 2023 as reported by Novartis patient specialty services and NBRx reported by data contracted specialty pharmacies.¹⁴      
**Based on Symphony Health Physician prescribing data and IQVIA Drug Distribution Data through March 2023, and IQVIA OneKey physician affiliation with practices who have prescribed at least 20 KESIMPTA prescriptions in the last 12 months.^{16       
††}Based on Symphony Health Anonymized Patient Level Data adjusted by IQVIA National Prescription Audit and National Sales Perspectives and Novartis contracted specialty pharmacy and copay claims data for January and February 2023.^{16      
‡‡}Treatment naive: 35%, first DMT: 29%.¹⁶

See the most frequently asked questions about KESIMPTA